{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:40:00Z","timestamp":1788921600351,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Patients with Type 2 diabetes are likely to have or to develop renal impairment, which affects the pharmacokinetics of some antidiabetic treatments.<\/jats:p><jats:p>\u2022\u2003Whether dosing of the once\u2010daily human glucagon\u2010like peptide\u20101 analogue liraglutide should be modified in patients with renal impairment has not previously been studied.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Renal dysfunction was not found to increase the exposure of liraglutide.<\/jats:p><jats:p>\u2022\u2003Hence, no dose adjustment is expected to be required in patients with Type 2 diabetes and renal impairment treated with liraglutide.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> To investigate whether dose adjustment of the once\u2010daily human glucagon\u2010like peptide\u20101 analogue liraglutide is required in patients with varying stages of renal impairment.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> A cohort of 30 subjects, of whom 24 had varying degrees of renal impairment and six had normal renal function, were given a single dose of liraglutide, 0.75\u2003mg subcutaneously, and completed serial blood sampling for plasma liraglutide measurements for pharmacokinetic estimation.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> No clear trend for change in pharmacokinetics was evident across groups with increasing renal dysfunction. While the between\u2010group comparisons of the area under the liraglutide concentration\u2013curve (AUC) did not demonstrate equivalence [estimated ratio AUC<jats:sub>severe<\/jats:sub>\/AUC<jats:sub>healthy<\/jats:sub> 0.73, 90% confidence interval (CI) 0.57, 0.94; and AUC (continuous ambulatory peritoneal dialysis)<jats:sub>CAPD<\/jats:sub>\/AUC<jats:sub>healthy<\/jats:sub> 0.74, 90% CI 0.56, 0.97], the regression analysis of log(AUC) for subjects with normal renal function and mild\u2010to\u2010severe renal impairment showed no significant effect of decreasing creatinine clearance on the pharmacokinetics of liraglutide. The expected AUC ratio between the two subjects with the lowest and highest creatinine clearance in the study was estimated to be 0.88 (95% CI 0.58, 1.34) (NS). Degree of renal impairment did not appear to be associated with an increased risk of adverse events.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> This study indicated no safety concerns regarding use of liraglutide in patients with renal impairment. Renal dysfunction was not found to increase exposure of liraglutide, and patients with Type 2 diabetes and renal impairment should use standard treatment regimens of liraglutide. There is, however, currently limited experience with liraglutide in patients beyond mild\u2010stage renal disease.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03536.x","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T11:45:14Z","timestamp":1251805514000},"page":"898-905","source":"Crossref","is-referenced-by-count":179,"title":["Effect of renal impairment on the pharmacokinetics of the GLP\u20101 analogue liraglutide"],"prefix":"10.1111","volume":"68","author":[{"given":"Lisbeth V.","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hindsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Zdravkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1620"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x"},{"key":"e_1_2_6_4_2","first-page":"1731","volume-title":"The Kidney","author":"Parving H\u2010H","year":"2000"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-8-199304150-00001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611283352203"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07368-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO\u2010HOPE substudy","volume":"355","author":"Heart Outcomes Prevention","year":"2000","journal-title":"Lancet"},{"key":"e_1_2_6_9_2","unstructured":"Glucophage Prescribing Information. Available athttp:\/\/www.fda.gov\/CDER\/foi\/label\/2000\/21202lbl.pdf(last accessed 10 November 2008)."},{"key":"e_1_2_6_10_2","unstructured":"Micronase (glyburide) Tablets Prescribing Information. Available athttp:\/\/media.pfizer.com\/files\/products\/uspi_micronase.pdf(last accessed 2 November 2008)."},{"key":"e_1_2_6_11_2","unstructured":"Glipizide Extended Release Tablets Prescribing Information. Available athttp:\/\/media.pfizer.com\/files\/products\/uspi_glipizide.pdf(last accessed 2 November 2008)."},{"key":"e_1_2_6_12_2","unstructured":"Precose (acarbose tablets) Prescribing Information. Available athttp:\/\/www.univgraph.com\/bayer\/inserts\/precose.pdf(last accessed 10 November 2008)."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02890.x"},{"key":"e_1_2_6_14_2","unstructured":"Byetta (exenatide injection) Prescribing Information. Available athttp:\/\/pi.lilly.com\/us\/byetta\u2010pi.pdf(last accessed 2 November 2008)."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.59.1.257"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200317020-00002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1358\/dnp.2003.16.7.829353"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-924230"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9909645"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-001-0719-z"},{"issue":"1","key":"e_1_2_6_22_2","first-page":"A581","article-title":"Metabolism and excretion of [Pal\u20103H]\u2010liraglutide in human healthy subjects","volume":"57","author":"Helleberg H","year":"2008","journal-title":"Diabetes"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00030.2002"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/db06-0565"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02189-1"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705397"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.03.013"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.06160"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2593"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2.424"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.7.1786"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.5.1187"},{"issue":"1","key":"e_1_2_6_34_2","first-page":"A0004","article-title":"Liraglutide significantly improves first\u2010phase insulin secretion and maximal beta\u2010cell secretory capacity","volume":"49","author":"Madsbad S","year":"2006","journal-title":"Diabetologia"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02333.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02484.x"},{"key":"e_1_2_6_37_2","unstructured":"Committee for Medicinal Products for Human Use.Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function. London:European Medicines Agency 2004. Available athttp:\/\/www.tga.gov.au\/DOCS\/pdf\/euguide\/ewp\/022502en.pdf(last accessed 4 June 2009)."},{"key":"e_1_2_6_38_2","volume-title":"Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function\u2014Study design, Data Analysis, and Impact on Dosing and Labeling","year":"1998"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00657.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920006776873490"},{"issue":"1","key":"e_1_2_6_42_2","first-page":"A145","article-title":"Influence of hepatic impairment on pharmacokinetics of the long\u2010acting human GLP\u20101 analogue liraglutide","volume":"56","author":"Flint A","year":"2007","journal-title":"Diabetes"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03536.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03536.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:08:21Z","timestamp":1697418501000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03536.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03536.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03536.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}